Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma

Cancer Letters

Volumn 292, Issue 2, 2010, Pages 208-214

  Wu, Lan ^a   Wang, Chong ^b,c   Zhang, Dapeng ^a   Zhang, Xunming ^a   Qian, Weizhu ^a,b   Zhao, Lei ^a   Wang, Hao ^a,b   Li, Bohua ^a,b   Guo, Yajun ^a,b,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b National Engineering Research Center for Antibody Medicine   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

B cell lymphoma; CD20; Complement dependent cytotoxicity; Humanized antibody

Indexed keywords

CD20 ANTIBODY; HU 8E4; RITUXIMAB; UNCLASSIFIED DRUG; CD20 ANTIGEN; MONOCLONAL ANTIBODY; PRIMER DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; PRIORITY JOURNAL; AMINO ACID SEQUENCE; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL; CRICETULUS; HAMSTER; IMMUNOLOGY; MOLECULAR GENETICS; MOUSE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY;

MUS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; BASE SEQUENCE; CHO CELLS; CRICETINAE; CRICETULUS; DNA PRIMERS; HUMANS; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 77951895824     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.12.004     Document Type: Article

References (23)

1. Tedder T.F., Streuli M., Schlossman S.F., Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc. Natl. Acad. Sci. USA 1988, 85:208-212.
2. Tedder T.F., Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today 1994, 15:450-454.
3. Maloney D.G. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J. Clin. Oncol. 2005, 23:6421-6428.
4. Cartron G., Watier H., Golay J., Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004, 104:2635-2642.
5. Glennie M.J., French R.R., Cragg M.S., Taylor R.P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 2007, 44:3823-3837.
6. Anderson D.R., Grillo-López A., Varns C., Chambers K.S., Hanna N. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem. Soc. Trans. 1997, 25:705-708.
7. McLaughlin P., Grillo-López A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., Heyman M.R., Bence-Bruckler I., White C.A., Cabanillas F., Jain V., Ho A.D., Lister J., Wey K., Shen D., Dallaire B.K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 1998, 16:2825-2833.
8. Eisenbeis C.F., Caligiuri M.A., Byrd J.C. Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma?. Clin. Cancer Res. 2003, 9:5810-5812.
9. Li B., Shi S., Qian W., Zhao L., Zhang D., Hou S., Zheng L., Dai J., Zhao J., Wang H., Guo Y. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res. 2008, 68:2400-2408.
10. Köhler G., Milstein C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur. J. Immunol. 1976, 6:511-519.
11. Qian W., Wang L., Li B., Wang H., Hou S., Hong X., Zhang D., Guo Y. Development of new versions of anti-human CD34 monoclonal antibodies with potentially reduced immunogenicity. Biochem. Biophys. Res. Commun. 2008, 367:497-502.
12. Kabat E.A., Wu T.T., Reid-Miller M., Perry H.M., Gottesman K.S. Sequences of proteins of immunological interest 1987, United States Department of Health and Human Services, Washington, DC. fourth ed.
13. Queen C., Schneider W.P., Selick H.E., Payne P.W., Landolfi N.F., Duncan J.F., Avdalovic N.M., Levitt M., Junghans R.P., Waldmann T.A. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA 1989, 86:10029-10033.
14. Pulito V.L., Roberts V.A., Adair J.R., Rothermel A.L., Collins A.M., Varga S.S., Martocello C., Bodmer M., Jolliffe L.K., Zivin R.A. Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A. J. Immunol. 1996, 156:2840-2850.
15. Nakamura K., Tanaka Y., Shitara K., Hanai N. Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions. Cancer Immunol. Immunother. 2001, 50:275-284.
16. Kettleborough C.A., Saldanha J., Heath V.J., Morrison C.J., Bendig M.M. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng. 1991, 4:773-783.
17. Wu H., Nie Y., Huse W.D., Watkins J.D. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. J. Mol. Biol. 1999, 294:151-162.
18. Kipriyanov S.M., Le Gall F. Generation and production of engineered antibodies. Mol. Biotechnol. 2004, 26:39-60.
19. Di Gaetano N., Cittera E., Nota R., Vecchi A., Grieco V., Scanziani E., Botto M., Introna M., Golay J. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 2003, 171:1581-1587.
20. Cragg M.S., Glennie M.J. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004, 103:2738-2743.
21. van der Kolk L.E., Grillo-López A.J., Baars J.W., Hack C.E., van Oers M.H. Complement activation plays a key role in the side-effects of rituximab treatment. Brit. J. Haematol. 2001, 115:807-811.
22. Manches O., Lui G., Chaperot L., Gressin R., Molens J.P., Jacob M.C., Sotto J.J., Leroux D., Bensa J.C., Plumas J. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003, 101:949-954.
23. Weng W.K., Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 2001, 98:1352-1357.